Orforglipron Results: How Much Weight Can You Lose?

Weeks 1–4: One Month

During the first month, orforglipron may start reducing appetite, food noise and cravings. Some people may notice they feel full sooner or naturally eat smaller portions.

You may not feel like you have lost weight, but the reduction in calories consumed should start to reflect the numbers on the scale.

Estimated weight loss:

1-3%

For someone weighing 100kg, this could mean roughly 1kg to 3kg in the first month.

Weeks 5–8: Two Months

By the second month, appetite control may become more consistent, especially as the dose is increased. Weight loss may become easier to notice, although progress can still fluctuate from week to week.

Estimated total weight loss by month two:

3-5%

For someone weighing 100kg, this could mean roughly 3kg to 5kg.

Weeks 9–12: Three Months

By three months, many people should have a clearer idea of how well they are responding. Hunger may be lower, portion sizes may reduce, and weight loss may become more visible.

Estimated total weight loss by month three:

5-8%

For someone weighing 100kg, this could mean roughly 5kg to 8kg.

Weeks 13–24: Six Months

By six months, trial data suggests orforglipron can produce more substantial results. In the Phase 2 trial, average weight loss at 26 weeks ranged from 8.6% to 12.6%, depending on the dose.

Estimated total weight loss by six months:

8-12%

For someone weighing 100kg, this could mean roughly 8kg to 12kg.

Weeks 25–52: One Year

By one year, weight loss may continue, although it often slows compared with the first few months. Longer-term results depend on dose, tolerability and whether the medication is combined with sustainable diet and lifestyle changes.

Estimated total weight loss by one year:

10-15%

For someone weighing 100kg, this could mean roughly 10kg to 14kg.

Phase 2 results

The first major obesity trial of orforglipron was a Phase 2 study in adults with obesity, or overweight with a weight-related condition.

At 26 weeks, average weight loss ranged from:

8.6% to 12.6%

At 36 weeks, average weight loss ranged from:

9.4% to 14.7%

The highest results were seen with higher doses. Importantly, a significant proportion of participants achieved clinically meaningful weight loss. By week 36, 46% to 75% of people taking orforglipron lost at least 10% of their body weight, compared with 9% taking placebo.

This suggests orforglipron can produce strong weight loss results, especially for people who respond well to GLP-1 appetite suppression.

Phase 3 results

The Phase 3 ATTAIN-1 trial looked at orforglipron in adults with obesity or overweight without type 2 diabetes.

At 72 weeks, average weight loss was reported as:

• 7.5% with 6mg (5.5mg tablet equivalent)
• 8.4% with 12mg (9mg tablet equivalent)
• 11.2% with 36mg (17.2mg tablet equivalent)
• 2.1% with placebo

Using a different efficacy analysis, the highest dose was reported to produce around 12.4% average weight loss, compared with 0.9% with placebo.

The ATTAIN-MAINTAIN trial included 376 adults who had previously completed 72 weeks of injectable treatment.

They were split into two groups: people previously treated with Mounjaro and people previously treated with Wegovy injections.

They were then randomised to either orforglipron once daily or placebo for 52 weeks.

In the ATTAIN-MAINTAIN trial, people who switched from Mounjaro or Wegovy injections to oral orforglipron maintained around 75-79% of their previous weight loss over 52 weeks, compared with 38-49% on placebo.

This suggests orforglipron may help reduce weight regain after stopping injectable treatment.

The results suggest that orforglipron is an effective oral GLP-1 option for weight loss.

It may not produce as much average weight loss as some of the strongest injectable treatments, such as Mounjaro, but the results are still clinically meaningful. Losing 10% or more of body weight can improve several obesity-related health risks, including blood pressure, blood sugar control, cholesterol and joint strain.

The main appeal of orforglipron is convenience. It is taken as a daily tablet, which may suit people who do not want injections or who prefer a simpler oral treatment option.

However, orforglipron is not a quick fix. The best results are seen over months, not days, and weight loss still depends heavily on consistency, diet, lifestyle and long-term adherence.

Orforglipron starts acting on GLP-1 receptors soon after you begin treatment, so some people may notice appetite changes within the first few days or weeks.

You may notice:

• reduced hunger
• feeling full sooner
• fewer cravings
• less snacking
• smaller portion sizes
• reduced “food noise”

Weight loss usually builds gradually. Some people may lose weight in the first month, but more visible results are usually seen after 8-12 weeks.

By 6 months, trial data suggests many people can achieve more noticeable weight loss, with Phase 2 results showing average weight loss of 8.6-12.6% at 6 months.

Take it consistently

Orforglipron is taken once daily. Missing doses regularly may reduce how well it works, especially for appetite control.

Follow the dosing schedule

GLP-1 medicines are usually increased gradually to improve tolerability and reduce side effects. Do not rush dose increases unless advised by your prescriber.

Further reading: Orforglipron dosage guide

Prioritise protein

Eating enough protein can help preserve muscle while losing weight. This is especially important if your appetite is much lower than usual.

Reduce high-fat and heavy meals

Greasy, rich or very large meals can make GLP-1 side effects worse, especially nausea, reflux, bloating and diarrhoea.

Stay hydrated

Reduced appetite can sometimes mean you eat and drink less without realising. Aim to drink regularly throughout the day.

Strength train where possible

Resistance training helps protect muscle mass during weight loss and can improve body composition.

Build long-term habits

The best results come when orforglipron is combined with sustainable habits. If you stop treatment and return to previous eating patterns, weight regain is possible.

Orforglipron can lead to meaningful weight loss, especially over several months.

Clinical trials suggest average weight loss of up to 14.7% at 36 weeks in Phase 2 and up to 12.4% at 72 weeks in Phase 3 at the highest dose.

For many people, the biggest benefit may be that orforglipron offers GLP-1 weight loss in tablet form. It may appeal to people who want an alternative to injections, although it is not currently licensed in the UK and should only be used if prescribed through a regulated healthcare provider.

Further reading: Where to buy orforglipron